NVAX

Novavax, Inc.
CAPPED RATING

Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax, Inc. (NVAX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (A-); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D-
Factor Score 0.8 / 5.0
Profitability
D
Factor Score 1.4 / 5.0
Momentum
A-
Factor Score 4.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -48.7
EV / EBITDA -20.1
Rev Growth YoY -3.0%
Gross Margin 5.3%
Price Return 3M 8.8%
Price Return 12M 17.7%
Catalyst Signal 0.00
Market Cap $1.4B
TTM Revenue $411.6M
Price / Sales 3.5
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) D- (0.8) D (1.4) A- (4.1) C+ (2.6) C (2.4)
2026-11-06 B- (3.0) D+ (1.8) D (1.3) A- (4.0) C+ (2.7) C+ (2.6)
2026-10-30 B- (3.0) D+ (1.8) D (1.4) A- (4.0) C+ (2.7) C+ (2.6)
2026-10-23 B- (3.0) D+ (1.8) D (1.4) B+ (3.8) C+ (2.6) C+ (2.5)
2026-10-16 B- (3.0) D+ (1.8) D (1.4) B (3.4) C+ (2.6) C (2.4)
Page 1 of 5